Phathom Pharmaceuticals has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating VOQUEZNA tablets for eosinophilic esophagitis in adults. The randomized, double-blind, placebo-controlled study enrolled 95 adults with endoscopically confirmed EoE and dysphagia, who were evenly randomized to receive VOQUEZNA 20 mg or placebo once daily for 12 weeks in Part 1. Patients completing Part 1 are eligible to enter a 12-week extension phase where all participants receive VOQUEZNA 20 mg once daily. Topline results are anticipated in the fourth quarter of 2026, and if positive, Phathom expects to discuss future development plans with the FDA, including pediatric evaluation.
Phathom Pharmaceuticals IncCompleted enrollment in Phase 2 trial for VOQUEZNA in eosinophilic esophagitis, a positive development step.